糖尿病治疗的新靶点——GLP-1类似物的临床应用
摘要
随着全球糖尿病发病率不断上升，糖尿病的发病机制和新药开发成为各国学术机构和开发商共同关注的目标，近年来糖尿病治疗的新靶点胰高血糖素样肽1（GLP-1）类似物也应运而生并开始应用于临床，GLP-1类似物作为糖尿病新药物的作用机制、疗效和安全性有待了解和经验总结。
出处
《实用医学杂志》
CAS
北大核心
2012年第16期2665-2668,共4页
The Journal of Practical Medicine
参考文献32
-
1Vendrell J, E1 B R, Peral B, et al. Study of the potential association of adipose tissue GLP-1 receptor with obesity and insulin resistance [J]. Endocrinology,2011,152 (11) : 4072- 4079.
-
2Van der Schueren B J, Homel P, Alam M, et al. Magnitude and variability of the glucagon-like peptide-1 response in patientswith type 2 diabetes up to 2 years following gastric bypass surgery [ J ]. Diabetes Care, 2012,35 ( 1 ) : 42-46.
-
3Buse J B, Henry R R, Han J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes[J]. Diabetes Care,2004,27( 11 ) : 2628-2635.
-
4DeFronzo R A, Ratner R E, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes [J].Diabetes Care. 2005.28 (5) : 1092-1100.
-
5Kendall D M, Riddle M C, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patientswith type 2 diabetes treated with metformin and a sulfonylurea[J]. Diabetes Care,2005,28(5): 1083-1091.
-
6Bunck M C, Diamant M, Comer A, et al. One-year treatment with exenatide improves beta-cell funetion, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial [ J ]. Diabetes Care, 2009,32 (5) : 762-768.
-
7Drucker D J, Buse J B, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study[J]. Lancet, 2008,372 (9645) : 1240-1250.
-
8Buse J B, Drucker D J, Taylor K L, et al. DURATION-l: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks [J]. Diabetes Care,2010,33 (6):1255-1261.
-
9Bergenstal R M, Wysham C, Macconell L, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazoneas an adjunct to metformin for treatment of type 2 diabetes (DURATION-2) : arandomised trial[J]. Lancet,2010, 376(9739) : 431-439.
-
10Wysham C, Bergenstal R, Malloy J, et al. DURATION-2: efficacy and safety of switching from maximum daily sitagliptin orpioglitazone to once-weekly exenatide[J]. Diabet Med,2011, 28(6) : 705-714.
-
1范维琥.从大规模临床试验的结果看冠心病患者调脂治疗的策略[J].上海医学,2005,28(4):267-269.
-
2刘红丽,王叶菊,郝建宁,李翊嘉.利拉鲁肽联合胰岛素治疗肥胖或超重的2型糖尿病患者疗效观察[J].中国基层医药,2012,19(18):2727-2728. 被引量：7
-
3朱红霞,梁新华,王敏哲.利拉鲁肽治疗阻塞性睡眠呼吸暂停综合征合并肥胖2型糖尿病患者的效果[J].中国老年学杂志,2015,35(6):1542-1544. 被引量：15
-
4李永玲,宋洁.利拉鲁肽治疗2型糖尿病12例疗效观察[J].医学信息,2012,25(8):547-547. 被引量：1
-
5哈丽达.木沙,玉山江.艾克木.利拉鲁肽治疗超重和肥胖2型糖尿病32例疗效观察[J].实用糖尿病杂志,2012,8(3):28-29. 被引量：4
-
6张贵山,高春斌,杨秀红,王文欣.利拉鲁肽治疗新诊断肥胖2型糖尿病疗效分析[J].河北医药,2013,35(18):2828-2828. 被引量：7
-
7胡大一,郭艺芳.2009年心脏病学进展[J].中国实用内科杂志,2010,30(2):99-101. 被引量：13
-
8邓卓军,赵彩彦.慢性丙型肝炎的抗病毒治疗[J].河北医药,2005,27(1):19-20. 被引量：1
-
9郑金洋,牛敬忠,聂莉,鲁克学.加用GLP-1类似物对改善糖尿病并阿尔茨海默病患者认知功能的效果观察[J].实用医药杂志,2017,34(2):145-146. 被引量：1
-
10本刊编辑部.关于投稿的相关事宜[J].眼科研究,2009,27(11):1049-1049.
